Page last updated: 2024-08-16

thalidomide and melphalan

thalidomide has been researched along with melphalan in 342 studies

Research

Studies (342)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	110 (32.16)	29.6817
2010's	214 (62.57)	24.3611
2020's	18 (5.26)	2.80

Authors

Authors	Studies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Anderson, KC; Chauhan, D; Davies, FE; Hideshima, T; Lin, B; Muller, G; Raje, N; Richardson, P; Schlossman, RL; Shima, Y; Stirling, DI; Tai, YT; Treon, SP	1
Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D	1
Huijgens, PC; Zweegman, S	1
Bello López, JL; Pérez-Encinas, M; Rabuñal Martínez, MJ	1
Cook, SD; Ropner, JE; Shuttleworth, GN	1
Dmoszyńska, A	1
Elson, P; Hussein, MA; Karam, MA; Srkalovic, G; Trebisky, B	1
Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M	1
Messori, A; Santarlasci, B; Trippoli, S	1
Aloi, G; Arrigo, C; La Gattuta, G; Micali, C; Pitini, V	1
Andretta, C; Annunziata, G; Catalano, L; Fonti, R; Pace, L; Rotoli, B	1
Anaissie, E; Barlogie, B; Crowley, J; Jacobson, J; Shaughnessy, J; Tricot, G; Walker, R; Zangari, M	1
Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M	1
Catarini, M; Corvatta, L; Leoni, P; Marconi, M; Offidani, M; Olivieri, A	1
Chehal, A; Elhajj, I; Mourad, YA; Shamseddine, A; Taher, A	1
Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S	1
Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A	1
Bertola, A; Boccadoro, M; Bringhen, S; Cavallo, F; Falco, P; Palumbo, A	1
Aikawa, S; Hatta, Y; Horie, T; Ito, T; Kanbe, E; Kitamura, K; Kura, Y; Oka, H; Saiki, M; Sawada, U; Takeuchi, J; Yamazaki, T	1
Jagannath, S	1
Anderson, KC; Palumbo, A	1
Dimopoulos, MA; Rahemtulla, A; Terpos, E	1
Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A	1
Joshua, DE	1
Kyle, RA; Rajkumar, SV	1
Brouwers, JR; Duyvendak, M; Kingma, BJ; Naunton, M	1
Barbui, AM; Barbui, T; Belfiglio, M; Crippa, C; Delaini, F; Galli, M; Giussani, U; Nicolucci, A; Rambaldi, A; Valentini, M	1
Anagnostopoulos, A; Anagnostopoulos, N; Delibasi, S; Dimopoulos, MA; Katodritou, E; Kyrtsonis, MC; Maniatis, A; Pouli, A; Repoussis, P; Terpos, E; Vassou, A; Zervas, K; Zomas, A	1
Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R	1
Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Palumbo, A	1
Kunihiko, M; Mariko, Y; Shinichiro, O; Yasuo, I; Yusuke, T; Yutaka, H	1
Anaissie, E; Barlogie, B; Crowley, J; Fassas, A; Fox, M; Hollmig, K; Kiwan, E; Krishna, S; Lee, C; Pineda-Roman, M; Rasmussen, E; Shaughnessy, J; Talamo, G; Thertulien, R; Tricot, G; van Rhee, F; Zangari, M	1
Baccarani, M; Cavo, M	1
Kumar, S	1
Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E	1
Coiteux, V; Facon, T; Leleu, X	1
Kyle, RA; Vincent Rajkumar, S	1
Burton, A	1
Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR	1
Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB	1
Cantelli, S; Catizone, L; Fabbian, F; Molino, C; Russo, G; Russo, M; Sartori, S; Stabellini, N	1
Okamoto, S	1
McKenna, KE; Morris, TC; Ramadan, KM	1
McGowan, N	1
Facon, T	2
Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P	1
Merlini, G; Palladini, G; Perfetti, V	1
Advani, SH; Ghosh, S; Gopal, R	1
Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P	1
Hoyer, RJ; Lacy, MQ; Leung, N; Witzig, TE	1
Iida, S	3
Strobeck, M	1
McLean, C; Patil, S; Schwarer, A	1
Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M	1
Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M	1
Hulin, C	1
Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Cottler-Fox, M; Crowley, J; Epstein, J; Gurley, J; Haessler, J; Hollmig, K; Jenkins, B; Mohiuddin, A; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Steward, D; Sullivan, E; Tricot, G; van Rhee, F; Zangari, M	1
Ludwig, H; Schreder, M; Strasser-Weippl, K; Zojer, N	1
Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y	1
Asou, N; Hata, H; Ide, K; Izuno, Y; Kawakita, M; Mitsuya, H; Okubo, T; Ueno, H	1
Fassas, AB; Tricot, G	1
Andreadis, C; Chong, EA; Glatstein, E; Goldstein, SC; Hummel, K; Liu, SV; Loren, AW; Luger, SM; Mangan, PA; Nasta, SD; Perl, A; Porter, DL; Schuster, SJ; Siegel, DL; Stadtmauer, EA; Tsai, DE; Vogl, DT	1
Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB	1
Chou, J; Cohen, AD; Comenzo, RL; Filippa, DA; Fleisher, M; Hassoun, H; Kewalramani, T; Levine, B; Nimer, S; Reich, L; Riedel, E; Stubblefield, MD; Teruya-Feldstein, J; Zhou, P	1
Boccadoro, M; Palumbo, A	1
Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I	1
Ganser, A; Peest, D	1
Faiman, B	1
Kamezaki, K; Nagafuji, K	1
Ishida, T	2
Gotoh, A; Ohyashiki, K	1
Darre, S; Facon, T	1
Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV	1
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Capaldi, A; Caravita, T; Cavallo, F; Cavo, M; Ciccone, G; Derudas, D; Dore, F; Falco, P; Falcone, A; Gay, F; Liberati, AM; Montanaro, M; Musto, P; Palumbo, A; Ria, R; Zambello, R	1
Garderet, L; Gorin, NC; Isnard, F	1
Facon, T; Hulin, C; Moreau, P	2
Kawamura, N; Kira, J	1
Callander, NS; Chang, JE; Gangnon, RE; Juckett, MB; Kahl, BS; Longo, WL; Mitchell, TL	1
Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K	1
Albertini, R; Bosoni, T; Lavatelli, F; Merlini, G; Moratti, R; Nuvolone, M; Obici, L; Palladini, G; Perfetti, V; Perlini, S; Russo, P	1
Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A	1
Bladé, J; Rosiñol, L	1
Boccadoro, M; Bringhen, S; D'Auria, F; Di Raimondo, F; Morabito, F; Musto, P; Palumbo, A; Pietrantuono, G; Pozzi, S; Sacchi, S	1
Adam, Z; Drach, J; Egyed, M; Gisslinger, H; Greil, R; Hajek, R; Hinke, A; Kuhn, I; Labar, B; Ludwig, H; Spicka, I; Tóthová, E; Zojer, N	1
Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N	1
Ambrus, JL; Islam, A	1
Avvisati, G	1
Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC	1
Higa, GM; Saad, AA; Sharma, M	1
Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A	1
Bradstock, KF; Coyle, L; Gill, DS; Horvath, N; Kennedy, N; Prince, HM; Prosser, IW; Reynolds, J; Roberts, AW; Spencer, A	1
Geffray, L	1
Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB	1
Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM	1
Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG	1
Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA	1
Deschler, B; Engelhardt, M; Ihorst, G; Jakob, C; Kleber, M; Koch, B; Liebisch, P; Sezer, O	1
Al-Kadhimi, Z; Alshekhlee, A; Djmil, M; Labro, H; Oghlakian, R	1
Baccarani, M; Ballerini, F; Bigazzi, C; Brioli, A; Califano, C; Casulli, AF; Cavo, M; Ceccolini, M; de Vivo, A; Di Raimondo, F; Fiacchini, M; Ledda, A; Offidani, M; Patriarca, F; Perrone, G; Stefani, P; Tacchetti, P; Tosi, P; Volpe, S; Zamagni, E	1
Brioli, A; Cavo, M; Pallotti, MC; Pantani, L; Petrucci, A; Tacchetti, P; Tosi, P; Zamagni, E	1
Berenschot, H; Bos, GM; Croockewit, S; de Weerdt, O; Delforge, M; Jie, KS; Joosten, P; Lokhorst, HM; Minnema, MC; Schaafsma, R; Sinnige, H; Sonneveld, P; van Ammerlaan, R; van der Holt, B; van Marwijk-Kooy, M; van Oers, MH; Vellenga, E; von dem Borne, P; Wijermans, P; Wittebol, S; Zweegman, S	1
Attal, M; Bourin, P; Laroche, M; Lemaire, O	1
Rowan, K	1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L	1
Kanda, Y	1
Ozaki, S	1
Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P	1
Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C	1
Azaïs, I; Brault, R; Debiais, F	1
Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F	1
Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C	1
Bauer, F; Dasanu, CA; Reale, MA	1
Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E	1
Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S	1
Alesiani, F; Brunori, M; Burattini, M; Catarini, M; Centurioni, R; Corvatta, L; Falcioni, S; Fraticelli, P; Galieni, P; Gentili, S; Leoni, P; Montanari, M; Offidani, M; Polloni, C; Ruggieri, M; Samori, A; Savini, A; Visani, G	1
Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G	1
Kuwabara, S	2
Bagratuni, T; Boyd, K; Davenport, EL; Davies, FE; Dickens, NJ; Gonzalez de Castro, D; Gregory, W; Johnson, DC; Morgan, GJ; Walker, BA; Wu, P	1
Alexanian, R; Delasalle, K; Giralt, S; Wang, M	1
Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F	1
Boccadoro, M; Dispenzieri, A; Falco, P; Gay, F; Gertz, MA; Keith Stewart, A; Kumar, S; Palumbo, A; Petrucci, MT; Vincent Rajkumar, S	1
Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G	1
Castelli, A; Conconi, A; Gaidano, G; Pinto, V	1
Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S	1
Lonial, S	1
Alakl, M; Benboubker, L; Bridoux, F; Fermand, JP; Harousseau, JL; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Moreau, P; Planche, L; Roussel, M; Royer, B; Salles, G	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB	1
Rajkumar, SV	2
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D	1
Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, S; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lust, JA; Rajkumar, SV; Russell, SJ; Zeldenrust, S	1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D	1
Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L	1
Boyd, KD; Chiecchio, L; Davies, FE; Morgan, GJ; Neri, A; Ross, FM; Smith, EM; Walker, BA; Wardell, CP	1
Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P	1
Palumbo, A	1
Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K	1
Harousseau, JL	2
Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M	1
Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V	1
Mateos, MV; San-Miguel, J	1
Schots, R	1
Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR	1
Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S	1
Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G	1
Kyle, RA; Steensma, DP	1
Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M	1
Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G	1
Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P	1
Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A	1
Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P	1
Bisi, MC; Dias, FS; do Prado, AD; Piovesan, DM; Schmoeller, D; Staub, HL	1
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W	1
Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S	1
Hawrylecka, D; Mensah-Glanowska, P; Piatkowska-Jakubas, B; Skotnicki, AB; Szostek, M; Walter, Z; Wolska-Smoleń, T	1
Falk, RH	1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I	1
D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O	1
Bryant, J; Clegg, AJ; Cooper, K; Picot, J	1
Landgren, O; Mailankody, S; Thomas, A	1
Min, CK	1
Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS	1
Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N	1
Chai, F; Malik, P	1
Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M	1
Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S	1
Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S	1
Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A	1
Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L	1
Domján, G; Gadó, K	1
Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF	1
Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M	1
Badros, AZ	1
Chocholska, S; Dmoszynska, A; Grzasko, N; Hajek, R; Hus, M; Jurczyszyn, A; Morawska, M; Pluta, A; Walter-Croneck, A	1
Arimura, K; Dispenzieri, A; Kuwabara, S; Misawa, S; Nakaseko, C	1
Charliński, G; Jedrzejczak, WW; Wiater, E	1
Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M	1
Barros, JC; Braggio, E; Chiattone, C; de Souza, CA; Garnica, M; Hungria, VT; Lima, CS; Lorand-Metze, I; Magalhães, RP; Maiolino, A; Mercante, DR; Miranda, EC; Nucci, M; Oliveira, LC; Oliveira-Duarte, G; Peres, AL; Quero, AA; Rego, EM; Renault, IZ; Tanaka, P	1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E	1
Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F	1
Bertolini, F	1
Ambaliya, A; Dosi, RV; Joshi, HJ; Patell, RD	1
Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M	1
Suzuki, K	2
Benevolo, G; Boccadoro, M; Bringhen, S; Carella, AM; Cavallo, F; De Paoli, L; Falco, P; Freilone, R; Gaidano, G; Gay, F; Grasso, M; Guglielmelli, T; Larocca, A; Mina, R; Molica, S; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Rocci, A; Rossi, D; Siez, ML	1
Beppu, M; Kanai, K; Kuwabara, S; Misawa, S; Mori, M; Moriya, J; Nakaseko, C; Nomura, F; Sawai, S; Shibuya, K; Sogawa, K; Taniguchi, J; Yamada, Y; Yamamoto, H	1
Giralt, S; Landau, H; Rosenzweig, M	1
Miwa, A	1
Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ	1
Patel, JM; Sanchorawala, V; Seldin, DC; Shelton, AC; Sloan, JM; Zeldis, JB	1
Gertz, MA; Hayman, SR; Sher, T	1
Hildebrandt, GC; Panu, LD; Shahan, JL	1
Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J	1
Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST	1
Lonial, S; Miguel, JF	1
Mina, R; Palumbo, A	1
Li, J; Zhou, DB	1
Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A	1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S	1
Afghahi, A; Arai, S; Dinner, S; Lafayette, R; Liedtke, M; Schrier, SL; Witteles, R; Witteles, W	1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A	1
Goldschmidt, H; Nitschmann, S	1
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G	1
Chevret, S; Facon, T; Mary, JY; Moatti, M; Moreau, P; Zohar, S	1
Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M	1
Barlogie, B; Dean, RM; Fennessey, SA; Finn, KT; Hoering, A; Holmberg, LA; Mattar, B; Orlowski, RZ; Safah, HF; Sanchorawala, V; Seldin, DC; Sexton, R	1
El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW	1
Morgan, GJ	1
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K	1
Drach, J; Drach-Schauer, B; Eder, S; Lamm, W	1
Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J	1
Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K	1
Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J	1
Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J	1
Amías-Lamana, V; Cabiró-Badimón, I; Hoyos-Chacón, J; Mesa-Gutiérrez, JC; Porta-Monnet, J; Rouras-López, A	1
Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S	1
Hahn, T; McCarthy, PL	1
Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y	1
Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R	1
Bryant, J; Clegg, A; Cooper, K; Picot, J	1
Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z	1
Brain, T; Khalafallah, A; Mohamed, M	1
Anderson, K; Barlogie, B; Boccadoro, M; Bringhen, S; Cavo, M; Ciccone, G; Dimopoulos, MA; Evangelista, A; Hajek, R; Kumar, SK; Larocca, A; Lonial, S; Lupparelli, G; McCarthy, PL; Musto, P; Nooka, AK; Offidani, M; Palumbo, A; Petrucci, MT; Richardson, P; Sonneveld, P; Spencer, A; Usmani, S; van der Holt, B; Waage, A; Zweegman, S	1
Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N	1
Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A	1
Cuyle, PJ; Delforge, M; Devos, T; Meersseman, W; Thiessen, S	1
Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M	1
Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT	1
Buckstein, R; Chesney, A; Cheung, M; Chodirker, L; Cussen, MA; Davidson, C; Kerbel, R; Lee, CR; Lenis, M; Mamedov, A; Reis, M; Shaked, Y; Wells, RA; Zhang, L	1
Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N	1
Aerts, JL; Corthals, J; De Keersmaecker, B; Fostier, K; Heirman, C; Schots, R; Thielemans, K; Wilgenhof, S	1
Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H	1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G	1
Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI	1
Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J	1
Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E	1
Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ	1
Avigan, D; Rosenblatt, J	1
Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M	1
Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL	1
Nakaseko, C	1
Tsurumi, H	1
Gooding, S; King, AJ; Ramasamy, K	1
Duan, M; Wen, Y	1
Bashir, Q; Champlin, RE; Cornelison, A; Fox, PS; Hosing, CM; Kebriaei, P; Lin, P; Nieto, Y; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ; Thall, PF	1
Arnulf, B; Bahlis, NJ; Canepa, L; Delforge, M; Eisenmann, JC; Ervin-Haynes, A; Escoffre-Barbe, M; Ezaydi, Y; Facon, T; Fragasso, A; Giraldo-Castellano, P; Guo, S; Houck, V; Langer, C; Lemieux, B; Leyvraz, S; Minuk, L; Monzini, MS; Song, K; Vogl, DT; Yoon, SS; Zarnitsky, C	1
Allred, J; Bergsagel, PL; Buadi, FK; Dispenzieri, A; Fonseca, R; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK	1
Hoskote, SS; Onigkeit, JA; Reddy, DR	1
Gandhi, V; He, J; Orlowski, RZ; Shentu, S; Stellrecht, CM; Yang, J; Zaman, S	1
Beksac, M; Bringhen, S; Fıratlı-Tuğlular, T; Gimsing, P; Juliusson, G; Kristinsson, SY; Lupparelli, G; Palumbo, A; Sucak, GT; Turesson, I; Waage, A	1
Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK	1
Cejalvo, MJ; de la Rubia, J	1
McCormack, PL	1
Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S	1
Bladé, J; García-Sanz, R; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Ocio, EM; Paiva, B; Rosiñol, L; San Miguel, JF	1
Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M	1
Alsina, M; Horna, P; Kharfan-Dabaja, MA; Nishihori, T; Salem, KZ	1
Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S	1
Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z	1
Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, YL; Kapoor, P; Kaufman, GP; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, S	1
Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI	1
Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W	1
Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A	1
Attal, M; Avet-Loiseau, H; Dejoie, T; Harousseau, JL; Moreau, P	1
Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R	1
Hellmich, M; Kuhr, K; Lehmacher, W; Srivastava, K; Wirth, D	1
Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB	1
Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S	1
Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC	1
Gertz, M; Muchtar, E	1
Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB	1
Cao, XX; Li, J; Liu, YH; Wang, T; Zhou, DB	1
An, N; Huang, ZX; Jiang, XX; Li, X; Shen, M; Zhang, JJ	1
Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K	1
Bahlis, NJ; Chen, BE; Chen, C; Djurfeldt, M; Han, M; Hay, AE; Howsen-Jan, K; Meyer, RM; Murugesan, A; Reece, D; Reiman, T; Seftel, MD; Shepherd, L; Song, K; Stewart, K; White, D; Xie, Y; Zhu, L	1
Liu, HB; Wang, W	1
Ahn, JS; Cho, MS; Choi, HJ; Hwang, EC; Jung, SH; Jung, TY; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Shin, MG; Yang, DH	1
Hogan, JJ; Weiss, BM	1
Alapat, D; Avery, D; Bailey, C; Barlogie, B; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Jethava, Y; Khan, R; Mitchell, A; Morgan, G; Petty, N; Sawyer, J; Schinke, C; Smith, R; Stein, C; Steward, D; Thanendrarajan, S; Tian, E; van Rhee, F; Waheed, S; Yaccoby, S; Zangari, M	1
Guo, C; He, P; Sun, C; Wang, X; Zhang, M	1
Choi, YS; Eom, HS; Han, JJ; Kang, HJ; Kim, HJ; Kim, K; Kim, MK; Kim, SH; Kwon, J; Lee, JH; Lee, JJ; Lee, JO; Lee, WS; Min, CK; Moon, JH; Yoon, DH; Yoon, SS	1
Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E	1
Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS	1
Coleman, M; Ely, S; Forsberg, P; Gergis, U; Greenberg, J; Guarneri, D; Jayabalan, D; Mark, TM; Mayer, S; Niesvizky, R; Pearse, R; Pekle, K; Perry, A; Rossi, A; Sherbenou, D; Shore, T; Tegnestam, L; Van Besien, K	1
Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM	1
Becker, N; Beimler, J; Benner, A; Bochtler, T; Freiberger, A; Gawlik, M; Goldschmidt, H; Hegenbart, U; Ho, AD; Hose, D; Hund, E; Jauch, A; Kimmich, C; Kristen, AV; Schönland, SO; Zorn, M	1
Bertsch, U; Blau, IW; Bos, GMJ; Broijl, A; Brossart, P; Croockewit, S; Duehrsen, U; Goldschmidt, H; Hielscher, T; Hillengass, J; Hose, D; Jarari, L; Jauch, A; Kersten, MJ; Lindemann, HW; Lokhorst, HM; Mai, EK; Pfreundschuh, M; Potamianou, A; Raab, MS; Raymakers, R; Salwender, HJ; Schaafsma, RM; Scheid, C; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van Marwijk Kooy, M; Vellenga, E; Weisel, KC; Ypma, P; Zweegman, S	1
Ballanti, S; Bringhen, S; Corvatta, L; Liberati, AM; Offidani, M; Pulini, S	1
Asumal, KB; Sattar, S; Zaidi, S	1
Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F	1
Peña, C; Quilodrán, JA; Valladares, X	1
Ludwig, H; Zojer, N	1
Baaj, ME; Doghmi, K; Eddou, H; Maaroufi, HE; Mikdame, M; Moudden, MK; Zinebi, A	1
Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S	1
Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L	1
D'Sa, S; Keddie, S; Lunn, MP	1
Ganly, P; Hock, BD; MacPherson, SA; McKenzie, JL; Mulholland, KS; Pearson, JF	1
Chen, W; Huang, X; Ren, G; Zuo, K	1
Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S	1
Bai, M; Liu, B; Sun, S; Wang, D; Wang, Y; Zhang, M; Zhao, J	1
Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C	1
Adachi, Y; Akashi, K; Choi, I; Fuchida, SI; Fujishima, N; Harada, M; Kiguchi, T; Kuroda, Y; Maeda, A; Matsumoto, M; Miyamoto, T; Nagafuji, K; Nakazato, T; Omoto, E; Sunami, K; Suzumiya, J; Takamatsu, H; Takamatsu, Y; Yamamura, R; Yujiri, T	1
Cao, Y; Jiang, J; Liang, Z; Lin, T; Wan, N; Wang, S; Xie, J; Zhang, T	1
Esparza, MAG; García-Chavez, J; Hernandez-Caballero, A; Majluf-Cruz, A; Montiel-Cervantes, LA; Reyes-Maldonado, E; Rodríguez-González, MG; Vela-Ojeda, J	1
Doki, N; Kosugi, H; Meguro, K; Murakami, H; Sasaki, O; Shimizu, K; Sunami, K; Suzuki, K; Takagi, T	1
Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E	1
Giuliani, N; Malavasi, F	1
Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S	1
Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S	1
Buchanan, V; D'Souza, VK; Dhanasiri, S; Ramasamy, K; Robinson, S; Thom, H; Weisel, K	1
Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J	1
Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS	1
Bernhard, H; Bertsch, U; Blau, IW; Brossart, P; Dürig, J; Elmaagacli, A; Fuhrmann, S; Giesen, N; Goerner, M; Goldschmidt, H; Hänel, M; Hielscher, T; Hillengass, J; Hoffmann, M; Hose, D; Hügle-Dörr, B; Huhn, S; Jauch, A; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Merz, M; Munder, M; Raab, MS; Rabold, B; Salwender, HJ; Scheid, C; Seckinger, A; Tichy, D; Weisel, KC	1
Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I	1
Dew, A; Hill, E; Kazandjian, D	1
Lu, SX	1
Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P	1
Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C	1
Chen, Y; Cutter, D; Loh, Y; Master, Z; Mikhaeel, G; Nagarajan, C; Thitsar, SM; Tin, KM; Yeoh, KW	1
Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D	1
Korst, CLBM; van de Donk, NWCJ	1
Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M	1
Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M	1
Alwafi, H; Awawdeh, SA; Liew, D; Naser, AY; Ofori-Asenso, R; Qadus, S	1

Reviews

86 review(s) available for thalidomide and melphalan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Treatment of myeloma: recent developments. Anti-cancer drugs, 2002, Volume: 13, Issue:4 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Humans; Interferons; Melphalan; Multiple Myeloma; Neoplasm Staging; Netherlands; Prednisone; Stem Cell Transplantation; Thalidomide	2002
[High dose chemotherapy and hematopoietic stem cell transplantation in patients with myeloma]. Polskie Archiwum Medycyny Wewnetrznej, 2001, Volume: 105 Suppl Topics: Humans; Melphalan; Multiple Myeloma; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide	2001
High-dose therapy and immunomodulatory drugs in multiple myeloma. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide	2002
Pharmacotherapy of multiple myeloma: an economic perspective. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:4 Topics: Aged; Cost-Benefit Analysis; Drug Therapy; Economics, Pharmaceutical; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thalidomide	2003
Treatment of multiple myeloma. Blood, 2004, Jan-01, Volume: 103, Issue:1 Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Gene Expression Profiling; History, 20th Century; History, 21st Century; Humans; Immunotherapy; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Renal Insufficiency; Salvage Therapy; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2004
Treatment of myeloma in patients not eligible for transplantation. Current treatment options in oncology, 2005, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide	2005
Current treatment options for myeloma. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine	2005
Multiple myeloma: diagnosis and treatment. Mayo Clinic proceedings, 2005, Volume: 80, Issue:10 Topics: Algorithms; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Retreatment; Stem Cell Transplantation; Thalidomide; Translocation, Genetic	2005
New treatments for multiple myeloma. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2005
[Prognostic factors and new treatments of multiple myeloma]. La Revue du praticien, 2006, Jan-15, Volume: 56, Issue:1 Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2006
Treatment of multiple myeloma: an emphasis on new developments. Annals of medicine, 2006, Volume: 38, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2006
[Recent progress in diagnosis of and therapy for multiple myeloma]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Sep-10, Volume: 95, Issue:9 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide	2006
What's wrong with this patient? Primary systemic amyloidosis. RN, 2006, Volume: 69, Issue:11 Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Diagnosis, Differential; Disease Progression; Early Diagnosis; Fatal Outcome; Female; Heart Failure; Humans; Immunosuppressive Agents; Mass Screening; Melphalan; Myeloablative Agonists; Nurse's Role; Patient Education as Topic; Pleural Effusion; Proteinuria; Rare Diseases; Stem Cell Transplantation; Thalidomide	2006
Therapy and management of systemic AL (primary) amyloidosis. Swiss medical weekly, 2006, Nov-11, Volume: 136, Issue:45-46 Topics: Amyloidosis; Dexamethasone; Glucocorticoids; Humans; Immunosuppressive Agents; Melphalan; Myeloablative Agonists; Prednisone; Stem Cell Transplantation; Thalidomide	2006
Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology, 2006, Volume: 70, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide	2006
[Recent progress in the treatment of multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:2 Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide	2007
[New treatment of multiple myeloma]. La Revue de medecine interne, 2007, Volume: 28, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide	2007
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 9 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2007
Tandem transplants in the treatment of multiple myeloma. Pro. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2004
[Therapy of multiple myeloma: indications and options]. Der Internist, 2007, Volume: 48, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden	2007
Clinical updates and nursing considerations for patients with multiple myeloma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome	2007
[POEMS syndrome: monoclonal plasma cell disorder with polyneuropathy]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Diagnosis, Differential; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; POEMS Syndrome; Prednisolone; Thalidomide; Vascular Endothelial Growth Factor A	2007
[Chemotherapy for multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine	2007
[Role of bortezomib in the treatment of multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Humans; Liposomes; Melphalan; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide	2007
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:4 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Thalidomide	2007
Frontline treatment of multiple myeloma in elderly patients. Blood reviews, 2008, Volume: 22, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide	2008
[Treatment strategy for POEMS syndrome]. Brain and nerve = Shinkei kenkyu no shinpo, 2008, Volume: 60, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Humans; Immunoglobulins; Melphalan; Peripheral Blood Stem Cell Transplantation; Plasma Exchange; POEMS Syndrome; Prednisolone; Prognosis; Radiotherapy; Surgical Procedures, Operative; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A	2008
[Treatment for multiple myeloma: current status and future strategy in Japan]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous	2008
Advances in therapy of multiple myeloma. Current opinion in oncology, 2008, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome	2008
Role of thalidomide in previously untreated patients with multiple myeloma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:10 Topics: Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Synergism; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Thalidomide	2008
Treatment of multiple myeloma in the targeted therapy era. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning	2009
Multiple myeloma. Lancet (London, England), 2009, Jul-25, Volume: 374, Issue:9686 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome	2009
[Hematopoietic stem cell transplantation for multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine	2009
[New treatment strategies for multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine	2009
New treatments for myeloma. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide	2010
New developments in the treatment of patients with multiple myeloma. The Netherlands journal of medicine, 2010, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide	2010
[Crow-Fukase (POEMS) syndrome]. Brain and nerve = Shinkei kenkyu no shinpo, 2010, Volume: 62, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Humans; Immunoglobulin lambda-Chains; Lenalidomide; Melphalan; Paraneoplastic Syndromes, Nervous System; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A	2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-20, Volume: 28, Issue:33 Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous	2010
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. American journal of hematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2011
Multiple myeloma in the elderly: when to treat, when to go to transplant. Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Transplantation, Autologous	2010
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. Revue neurologique, 2011, Volume: 167, Issue:1 Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Drug Therapy, Combination; Early Diagnosis; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin lambda-Chains; Melphalan; Paraproteinemias; Peripheral Nerves; POEMS Syndrome; Prednisone; Salivary Glands, Minor; Skin; Thalidomide; Vascular Endothelial Growth Factor A	2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia, 2011, Volume: 25, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplants; Treatment Outcome	2011
Treatment of newly diagnosed myeloma in patients not eligible for transplantation. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2011
[Current treatment of AL amyloidosis]. Nephrologie & therapeutique, 2011, Volume: 7, Issue:6 Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide	2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2011
[New insights in the treatment of myeloma with renal failure]. Nephrologie & therapeutique, 2011, Volume: 7, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide	2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood, 2011, Aug-04, Volume: 118, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide	2011
[New treatment strategy for Crow-Fukase (POEMS) syndrome]. Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Combined Modality Therapy; Demyelinating Diseases; Humans; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A	2010
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:41 Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide	2011
[Multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid	2012
[AL amyloidosis]. Orvosi hetilap, 2012, Apr-15, Volume: 153, Issue:15 Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2012
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. The Cochrane database of systematic reviews, 2012, Jun-13, Issue:6 Topics: Adrenal Cortex Hormones; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; POEMS Syndrome; Retrospective Studies; Thalidomide	2012
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:8 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induced Liver Injury; Darbepoetin alfa; Diazepam; Erythropoietin; Fatal Outcome; Humans; Jaundice, Obstructive; Liver Function Tests; Male; Melphalan; Multiple Myeloma; Omeprazole; Pneumonia; Polypharmacy; Prednisolone; Thalidomide	2012
Fifty years of melphalan use in hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3 Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous	2013
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and experimental nephrology, 2012, Volume: 16, Issue:5 Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide	2012
Light-chain amyloidosis: SCT, novel agents and beyond. Bone marrow transplantation, 2013, Volume: 48, Issue:8 Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide	2013
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome	2012
Current therapeutic strategy for multiple myeloma. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2 Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid	2013
Induction therapy for newly diagnosed multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2013
Part II: role of maintenance therapy in transplant-ineligible patients. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine	2013
New advances in the diagnosis and treatment of POEMS syndrome. British journal of haematology, 2013, Volume: 161, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A	2013
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013 Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning	2013
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. The Lancet. Oncology, 2014, Volume: 15, Issue:3 Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide	2014
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2014
[Treatment of transplant-eligible symptomatic multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning	2014
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide	2014
Managing multiple myeloma in the over 70s: a review. Maturitas, 2015, Volume: 80, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Density Conservation Agents; Bortezomib; Comorbidity; Cyclophosphamide; Dexamethasone; Diphosphonates; Fractures, Compression; Geriatric Assessment; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Palliative Care; Stem Cell Transplantation; Thalidomide; Vertebroplasty	2015
[Successful treatment with melphalan, dexamethasone and thalidomide for relapsed idiopathic light chain deposit disease: a case report and literature review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:1 Topics: Dexamethasone; Humans; Melphalan; Multiple Myeloma; Recurrence; Thalidomide	2015
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Future oncology (London, England), 2015, Volume: 11, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide	2015
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. Drugs & aging, 2015, Volume: 32, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2015
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide	2015
Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood reviews, 2015, Volume: 29, Issue:6 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Precision Medicine; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2015
Maintenance therapy for multiple myeloma in the era of novel agents. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2015
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. European journal of clinical pharmacology, 2016, Volume: 72, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Germany; Humans; Melphalan; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Thalidomide	2016
Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. Chinese medical journal, 2016, Feb-05, Volume: 129, Issue:3 Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Thalidomide	2016
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Clinical journal of the American Society of Nephrology : CJASN, 2016, 09-07, Volume: 11, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine	2016
Fixed duration vs continuous therapy in multiple myeloma. Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free Survival; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Rate; Thalidomide; Time Factors	2017
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica, 2019, Volume: 104, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome	2019
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2019
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leukemia & lymphoma, 2020, Volume: 61, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Network Meta-Analysis; Thalidomide; Treatment Outcome	2020
Second malignancies in multiple myeloma; emerging patterns and future directions. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Neoplasms, Second Primary; Risk Factors; Thalidomide; Transplantation, Autologous	2020
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future! Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Risk Factors; Survival Analysis; Thalidomide; Transplantation, Autologous	2020
Modern treatments and future directions for newly diagnosed multiple myeloma patients. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Survival Analysis; Thalidomide; Transplantation, Autologous	2020
Should all newly diagnosed MM patients receive CD38 antibody-based treatment? Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1 Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Neoplasm Proteins; Thalidomide	2020
Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:10 Topics: Humans; Lenalidomide; Medication Adherence; Melphalan; Multiple Myeloma; Panobinostat; Pharmaceutical Preparations; Thalidomide	2022

Trials

101 trial(s) available for thalidomide and melphalan

Article	Year
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000, Nov-01, Volume: 96, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; DNA Replication; Doxorubicin; Drug Resistance, Multiple; Female; G1 Phase; Humans; Immunosuppressive Agents; Male; Melphalan; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured	2000
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone marrow transplantation, 2003, Volume: 31, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Salvage Therapy; Thalidomide; Vincristine	2003
Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica, 2003, Volume: 88, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Venous Thrombosis	2003
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. European journal of haematology, 2004, Volume: 72, Issue:6 Topics: Aged; Aged, 80 and over; Constipation; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Probability; Thalidomide; Venous Thrombosis	2004
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide	2004
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica, 2006, Volume: 91, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Remission Induction; Thalidomide; Venous Thrombosis	2006
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. European journal of haematology, 2006, Volume: 76, Issue:4 Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome	2006
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. The New England journal of medicine, 2006, Mar-09, Volume: 354, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Survival Rate; Thalidomide	2006
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet (London, England), 2006, Mar-11, Volume: 367, Issue:9513 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2006
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide	2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide	2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica, 2007, Volume: 92, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Proteinuria; Pyrazines; Thalidomide; Treatment Outcome; Vincristine	2007
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome	2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British journal of haematology, 2007, Volume: 138, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide	2007
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British journal of haematology, 2007, Volume: 139, Issue:2 Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Adult; Aged; Amyloidosis; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Remission Induction; Risk Assessment; Survival Rate; Thalidomide; Transplantation, Autologous	2007
A new standard of care for elderly patients with myeloma. Lancet (London, England), 2007, Oct-06, Volume: 370, Issue:9594 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Delivery of Health Care; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide	2007
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet (London, England), 2007, Oct-06, Volume: 370, Issue:9594 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide	2007
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, Oct-15, Volume: 112, Issue:8 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Follow-Up Studies; Humans; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2008
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:3 Topics: Adolescent; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous	2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 2008, Volume: 22, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide	2008
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of hematology, 2009, Volume: 88, Issue:4 Topics: Aged; Amyloidosis; Dexamethasone; Drug Therapy, Combination; Female; Heart Diseases; Heart Failure; Humans; Male; Melphalan; Middle Aged; Stroke Volume; Survival Rate; Thalidomide; Treatment Outcome	2009
Update on recent developments for patients with newly diagnosed multiple myeloma. Annals of the New York Academy of Sciences, 2008, Volume: 1138 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2008
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood, 2009, Apr-09, Volume: 113, Issue:15 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prednisolone; Survival Rate; Thalidomide; Treatment Outcome	2009
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Glucocorticoids; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous	2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia	2009
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Probability; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Thalidomide; Treatment Outcome	2009
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-20, Volume: 27, Issue:21 Topics: Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide; Time Factors; Transplantation, Autologous	2009
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood, 2010, Feb-11, Volume: 115, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Young Adult	2010
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip Annals of hematology, 2010, Volume: 89, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome	2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome	2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica, 2010, Volume: 95, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Melphalan; Multiple Myeloma; Polydeoxyribonucleotides; Prednisone; Salvage Therapy; Thalidomide; Treatment Outcome	2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. European journal of haematology, 2010, Volume: 84, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Multiple Myeloma; Polyethylene Glycols; Prospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome	2010
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010, Volume: 24, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2010
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood, 2010, Jul-15, Volume: 116, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dexamethasone; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Regulatory Factor X Transcription Factors; Thalidomide; Transcription Factors; Vincristine; X-Box Binding Protein 1	2010
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood, 2010, Sep-02, Volume: 116, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Melphalan; Multiple Myeloma; Placebos; Prednisone; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome	2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neutropenia; Pain; Prednisone; Quality of Life; Regression Analysis; Thalidomide; Treatment Outcome	2010
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Adult; Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Thalidomide	2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome	2010
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. European journal of haematology, 2011, Volume: 86, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Female; Humans; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Opportunistic Infections; Prednisone; Survival Analysis; Thalidomide; Treatment Outcome	2011
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood, 2011, Jan-13, Volume: 117, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cluster Analysis; Cyclophosphamide; Dexamethasone; Disease Progression; DNA Methylation; Doxorubicin; Humans; In Situ Hybridization, Fluorescence; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Precancerous Conditions; Prednisolone; Prognosis; Stem Cell Transplantation; Thalidomide; Vincristine	2011
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Annals of hematology, 2011, Volume: 90, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Models, Statistical; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome	2011
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leukemia & lymphoma, 2011, Volume: 52, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide; Treatment Outcome	2011
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. American journal of hematology, 2011, Volume: 86, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2011
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood, 2011, Sep-01, Volume: 118, Issue:9 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Drug Eruptions; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation	2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood, 2011, Nov-24, Volume: 118, Issue:22 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome	2011
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2012, Volume: 53, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neutropenia; Panobinostat; Prednisone; Recurrence; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome	2012
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European journal of haematology, 2012, Volume: 88, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide	2012
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide	2012
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American journal of hematology, 2012, Volume: 87, Issue:10 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Thalidomide; Transplantation, Autologous; Vincristine	2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia, 2013, Volume: 27, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Thalidomide	2013
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2013
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 2013, Volume: 98, Issue:5 Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Thalidomide; Treatment Outcome	2013
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica, 2013, Volume: 98, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Surveys and Questionnaires; Thalidomide	2013
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 2013, Volume: 98, Issue:10 Topics: Aged; Aged, 80 and over; Amyloidosis; Cohort Studies; Dexamethasone; Drug Therapy, Combination; Female; Heart Diseases; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Pilot Projects; Survival Rate; Thalidomide	2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, Aug-22, Volume: 122, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. Clinical trials (London, England), 2013, Volume: 10, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bayes Theorem; Drug Therapy, Combination; Expert Testimony; Humans; Melphalan; Models, Statistical; Multiple Myeloma; Myeloablative Agonists; Prednisone; Stem Cell Transplantation; Surveys and Questionnaires; Survival Analysis; Thalidomide	2013
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone marrow transplantation, 2013, Volume: 48, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia & lymphoma, 2014, Volume: 55, Issue:7 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Quality of Life; Thalidomide; Treatment Outcome	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome	2014
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. European journal of haematology, 2014, Volume: 93, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome	2014
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leukemia research, 2014, Volume: 38, Issue:7 Topics: Aged; Aged, 80 and over; Biomarkers; Endothelial Cells; Humans; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prospective Studies; Thalidomide; Vascular Endothelial Growth Factor A	2014
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology, 2014, Volume: 87, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Thalidomide	2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood, 2014, Sep-18, Volume: 124, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2014
Autologous transplantation and maintenance therapy in multiple myeloma. The New England journal of medicine, 2014, Sep-04, Volume: 371, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England journal of medicine, 2014, Sep-04, Volume: 371, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2014
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia, 2015, Volume: 29, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Thalidomide; Transplantation, Autologous; Treatment Outcome	2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica, 2015, Volume: 100, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Female; Health Status; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide	2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood cancer journal, 2015, Mar-20, Volume: 5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood, 2015, Sep-10, Volume: 126, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide	2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Oct-20, Volume: 33, Issue:30 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2015
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood, 2016, Jan-28, Volume: 127, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2016
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome	2015
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica, 2016, Volume: 101, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Bortezomib; Dexamethasone; Electrophoresis; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Melphalan; Multiple Myeloma; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Retrospective Studies; Thalidomide; Transplantation, Homologous	2016
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica, 2016, Volume: 101, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome	2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, Apr-14, Volume: 127, Issue:15 Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide	2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome; Withholding Treatment	2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 06-23, Volume: 127, Issue:25 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine	2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 10-20, Volume: 34, Issue:30 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide	2016
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal, 2016, 07-29, Volume: 6, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Thalidomide	2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. American journal of hematology, 2017, Volume: 92, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden	2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. British journal of haematology, 2017, Volume: 176, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome	2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:6 Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia, 2017, Volume: 31, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica, 2017, Volume: 102, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Remission Induction; Survival Analysis; Thalidomide	2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia, 2018, Volume: 32, Issue:2 Topics: Adolescent; Adult; Aged; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Progression-Free Survival; Thalidomide; Transplantation, Autologous; Young Adult	2018
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2018, Volume: 59, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prednisone; Prognosis; Survival Rate; Thalidomide	2018
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. American journal of hematology, 2019, Volume: 94, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazoles; Pyridones; Thalidomide; Venous Thromboembolism	2019
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12). International journal of clinical oncology, 2019, Volume: 24, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prognosis; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous	2019
Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. International journal of hematology, 2019, Volume: 110, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Survival Rate; Thalidomide	2019
Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem International journal of hematology, 2019, Volume: 110, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Autografts; Double-Blind Method; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia, 2020, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2020
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 2020, Volume: 105, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Thalidomide	2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). American journal of hematology, 2020, Volume: 95, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide	2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 2020, Volume: 34, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Transplantation, Autologous	2020
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future oncology (London, England), 2020, Volume: 16, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide	2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, 2020, 08-27, Volume: 136, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine	2020
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Cancer medicine, 2020, Volume: 9, Issue:23 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States	2020
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. The Lancet. Haematology, 2022, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide	2022

Other Studies

155 other study(ies) available for thalidomide and melphalan

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone marrow transplantation, 2002, Volume: 29, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Vincristine	2002
Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica, 2002, Volume: 87, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Electrocoagulation; Gastrointestinal Hemorrhage; Humans; Male; Melphalan; Multiple Myeloma; Recurrence; Telangiectasia, Hereditary Hemorrhagic; Thalidomide	2002
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia. The British journal of ophthalmology, 2002, Volume: 86, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Corneal Diseases; Cyclophosphamide; Doxorubicin; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteinemias; Thalidomide; Visual Acuity	2002
Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Medical oncology (Northwood, London, England), 2002, Volume: 19, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Melphalan; Multiple Myeloma; Prognosis; Survival Rate; Thalidomide	2002
99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients. Leukemia & lymphoma, 2003, Volume: 44, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Thalidomide; Tissue Distribution	2003
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Annals of hematology, 2004, Volume: 83, Issue:7 Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Idarubicin; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Vincristine	2004
Hb H disease and multiple myeloma. Hemoglobin, 2004, Volume: 28, Issue:1 Topics: Aged; alpha-Thalassemia; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Splenectomy; Thalidomide	2004
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Platelet Transfusion; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Thalidomide	2004
[Multiple myeloma of the IgD-lambda type invading CNS]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Immunoglobulin D; Injections, Spinal; Interferon-alpha; Melphalan; Meningeal Neoplasms; Methotrexate; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Invasiveness; Nitrosourea Compounds; Prednisolone; Radiotherapy, Adjuvant; Thalidomide; Vincristine	2004
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4 Topics: Age Factors; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Drug Therapy, Combination; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide	2005
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer, 2005, Oct-01, Volume: 104, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome	2005
Multiple myeloma: the present and the future. The Medical journal of Australia, 2005, Oct-03, Volume: 183, Issue:7 Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2005
Thalidomide-associated thrombocytopenia. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:11 Topics: Administration, Oral; Aged; Dexamethasone; Female; Humans; Melphalan; Multiple Myeloma; Neutropenia; Prednisolone; Thalidomide; Thrombocytopenia; Treatment Outcome	2005
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Haematologica, 2005, Volume: 90, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation	2005
Thalidomide for the treatment of leptomeningeal multiple myeloma. European journal of haematology, 2006, Volume: 76, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunoglobulin G; Melphalan; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Thalidomide; Vindesine	2006
The changing landscape of myeloma therapy. The New England journal of medicine, 2006, Mar-09, Volume: 354, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide	2006
Progress in the treatment of multiple myeloma. Lancet (London, England), 2006, Mar-11, Volume: 367, Issue:9513 Topics: Aged; Antineoplastic Agents, Alkylating; Disease-Free Survival; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisolone; Randomized Controlled Trials as Topic; Thalidomide	2006
Thalidomide gives food for thought in multiple myeloma. The Lancet. Oncology, 2006, Volume: 7, Issue:4 Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Risk Factors; Survival Analysis; Thalidomide; Venous Thrombosis	2006
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:8 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors	2006
Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis. The International journal of artificial organs, 2006, Volume: 29, Issue:8 Topics: Amyloidosis; Anti-Inflammatory Agents; Bicarbonates; Buffers; Cardiac Output, Low; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Melphalan; Middle Aged; Natriuretic Peptide, Brain; Nephrotic Syndrome; Prednisolone; Renal Dialysis; Thalidomide; Treatment Outcome	2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. The Lancet. Oncology, 2006, Volume: 7, Issue:11 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid	2006
Advances in the treatment of elderly patients with multiple myeloma. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide	2006
Myelomatous pleural effusion. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Humans; Melphalan; Multiple Myeloma; Pleural Effusion, Malignant; Prognosis; Pulse Therapy, Drug; Recurrence; Thalidomide; Vincristine	2006
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. American journal of hematology, 2007, Volume: 82, Issue:5 Topics: Amyloidosis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Captopril; Chest Tubes; Combined Modality Therapy; Dexamethasone; Diuretics; Drug Resistance; Edema; Fatal Outcome; Furosemide; Humans; Hypoalbuminemia; Male; Melphalan; Metolazone; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Pleural Effusion; Prednisolone; Serum Albumin; Spironolactone; Thalidomide; Thoracostomy; Transplantation, Autologous; Vascular Endothelial Growth Factor A	2007
Multiple myeloma therapies. Nature reviews. Drug discovery, 2007, Volume: 6, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide	2007
Urinary cytology in multiple myeloma. Cytopathology : official journal of the British Society for Clinical Cytology, 2008, Volume: 19, Issue:2 Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Kidney Neoplasms; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Plasma Cells; Plasmacytoma; Prednisolone; Thalidomide; Urine	2008
Refractory multiple myeloma treated with homoharringtonine: report of two cases. Annals of hematology, 2007, Volume: 86, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine	2007
Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma. International journal of hematology, 2007, Volume: 86, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide	2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. American journal of hematology, 2007, Volume: 82, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine	2007
Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer, 2008, Apr-01, Volume: 112, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Incidence; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prednisone; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis	2008
[Treatment of myeloma in the elderly]. Bulletin du cancer, 2008, May-28, Volume: 95 FMC Onco Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide	2008
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. International journal of oncology, 2008, Volume: 33, Issue:6 Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine	2008
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2008
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide	2008
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. International journal of hematology, 2009, Volume: 89, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglobulin Light Chains; Ischemia; Lenalidomide; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Thalidomide	2009
Cutaneous involvement in multiple myeloma and bortezomib. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia	2009
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux]. La Revue de medecine interne, 2009, Volume: 30, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; France; Humans; Internal Medicine; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Societies, Medical; Thalidomide	2009
Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment. Prescrire international, 2009, Volume: 18, Issue:100 Topics: Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Europe; Female; Humans; Male; Melphalan; Multiple Myeloma; Orphan Drug Production; Prednisone; Survival; Thalidomide	2009
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Combined Modality Therapy; Comorbidity; Creatinine; Dexamethasone; Doxorubicin; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Retrospective Studies; Risk Assessment; Thalidomide; Treatment Outcome; Vincristine	2009
Brain amyloidoma with cerebral hemorrhage. The Journal of the American Osteopathic Association, 2009, Volume: 109, Issue:7 Topics: Amyloidosis; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dexamethasone; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Melphalan; Middle Aged; Thalidomide; Valproic Acid	2009
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Doxorubicin; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine	2009
Thalidomide maintenance in multiple myeloma: certainties and controversies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Glucocorticoids; Humans; Melphalan; Multiple Myeloma; Prednisolone; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous	2009
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma. European journal of haematology, 2010, Volume: 84, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine	2010
Researchers debate best use of stem cell transplants in patients with multiple myeloma. Journal of the National Cancer Institute, 2009, Dec-02, Volume: 101, Issue:23 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2009
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. European journal of haematology, 2010, Volume: 84, Issue:3 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine	2010
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European journal of haematology, 2010, Volume: 84, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide	2010
Treatment of multiple myeloma: 2009 update. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine	2009
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide. Leukemia research, 2010, Volume: 34, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous	2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of hematology, 2010, Volume: 89, Issue:8 Topics: Aged; Consensus; Europe; Guidelines as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Risk Factors; Survival Rate; Thalidomide; Thromboembolism	2010
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous	2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. European journal of haematology, 2010, Volume: 85, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome	2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. Leukemia & lymphoma, 2010, Volume: 51, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Polyethylene Glycols; Prednisone; Survival Rate; Thalidomide; Treatment Outcome	2010
Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure. American journal of hematology, 2010, Volume: 85, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Combined Modality Therapy; Cyclams; Dexamethasone; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kidney Failure, Chronic; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Renal Dialysis; Thalidomide; Transplantation Conditioning	2010
Frontline regimens for multiple myeloma patients. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2010
Optimising bortezomib in newly diagnosed multiple myeloma. The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome	2010
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. American journal of hematology, 2010, Volume: 85, Issue:10 Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Patient Dropouts; Peptide Fragments; Stem Cell Transplantation; Thalidomide; Troponin T	2010
First-line treatment of elderly multiple myeloma patients. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2010
Recent advances in myeloma treatment. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2011, Volume: 44, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide	2011
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous	2011
History of multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane	2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of hematology, 2012, Volume: 91, Issue:1 Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2012
Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis? International journal of dermatology, 2012, Volume: 51, Issue:8 Topics: Brain Diseases; Coma; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Myeloablative Agonists; Paraproteinemias; Plasmapheresis; Prednisone; Scleromyxedema; Thalidomide; Treatment Outcome	2012
[High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience]. Przeglad lekarski, 2011, Volume: 68, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous	2011
Cardiac amyloidosis: a treatable disease, often overlooked. Circulation, 2011, Aug-30, Volume: 124, Issue:9 Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine	2012
Myeloma and second primary cancers. The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23 Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Probability; Risk Assessment; Thalidomide	2011
Is the low-thalidomide dose MPT regimen beneficial? The Korean journal of internal medicine, 2011, Volume: 26, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2011
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. The Korean journal of internal medicine, 2011, Volume: 26, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Confidence Intervals; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Risk; Thalidomide; Time Factors; Treatment Outcome	2011
Drug interaction between lenalidomide and itraconazole. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide	2012
AL amyloidosis in a patient with macroglossia. ANZ journal of surgery, 2011, Volume: 81, Issue:11 Topics: Aged; Amyloidosis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Macroglossia; Magnetic Resonance Imaging; Melphalan; Prednisolone; Risk Assessment; Severity of Illness Index; Thalidomide; Treatment Outcome	2011
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer research, 2012, Mar-15, Volume: 72, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide	2012
Timing of the high-dose therapy in the area of new drugs. Srpski arhiv za celokupno lekarstvo, 2011, Volume: 139 Suppl 2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2011
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp Vnitrni lekarstvi, 2012, Volume: 58, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous	2012
Multiple myeloma: treatment evolution. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult	2012
Lenalidomide in myeloma--a high-maintenance friend. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2012
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematological oncology, 2013, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Gene Amplification; Hemoglobins; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prednisone; Prognosis; Remission Induction; Thalidomide	2013
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190 Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide	2012
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11 Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation	2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine	2013
Lenalidomide for multiple myeloma. The New England journal of medicine, 2012, 08-09, Volume: 367, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2012
A rare case of plasma cell leukemia in a 35 year old. Indian journal of medical sciences, 2010, Volume: 64, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Plasma Cell; Male; Melphalan; Prednisolone; Thalidomide	2010
How to select among available options for the treatment of multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Multiple angiogenetic factors are upregulated in POEMS syndrome. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Hepatocyte Growth Factor; Humans; Male; Melphalan; Middle Aged; POEMS Syndrome; Thalidomide; Up-Regulation; Vascular Endothelial Growth Factor A	2013
[Diagnosis and treatment for plasma cell leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide	2012
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy. Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:10 Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone. International journal of hematology, 2012, Volume: 96, Issue:6 Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide	2012
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan The oncologist, 2013, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States	2013
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10 Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Male; Melphalan; POEMS Syndrome; Polysomnography; Prednisolone; Pulmonary Wedge Pressure; Sleep Apnea Syndromes; Thalidomide; Ultrasonography; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left	2013
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10 Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine	2013
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. British journal of haematology, 2013, Volume: 162, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy	2013
[New treatment strategies for multiple myeloma]. Der Internist, 2013, Volume: 54, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leukemia research, 2013, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult	2013
Multiple myeloma: a descriptive study of 217 Egyptian patients. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine	2014
Transplants for the elderly in myeloma. Blood, 2013, Aug-22, Volume: 122, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide	2013
Myeloma presenting during pregnancy. Hematological oncology, 2014, Volume: 32, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous	2014
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology, 2013, Volume: 85, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome	2013
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:5 Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome	2013
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. European journal of haematology, 2014, Volume: 92, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retreatment; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome	2014
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous	2014
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy]. Archivos de la Sociedad Espanola de Oftalmologia, 2013, Volume: 88, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corneal Opacity; Crystallization; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney Failure, Chronic; Lenalidomide; Male; Melphalan; Middle Aged; Paraproteinemias; Paraproteins; Phacoemulsification; Postoperative Complications; Prednisone; Slit Lamp; Thalidomide	2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome	2014
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma. Anticancer research, 2013, Volume: 33, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning	2013
Comparative cost-effectiveness models for the treatment of multiple myeloma. International journal of technology assessment in health care, 2014, Volume: 30, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom	2014
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia, 2014, Volume: 28, Issue:8 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9	2014
Dramatic response of diffuse osteosclerosis secondary to multiple myeloma using thalidomide with melphalan and prednisolone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Aug-10, Volume: 32, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Melphalan; Multiple Myeloma; Osteosclerosis; Prednisolone; Thalidomide	2014
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. International journal of hematology, 2014, Volume: 99, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome	2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2014
Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years. Annals of hematology, 2014, Volume: 93, Issue:11 Topics: Adult; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Male; Melphalan; Nervous System Diseases; Scleromyxedema; Stem Cell Transplantation; Syndrome; Thalidomide; Time Factors; Treatment Outcome	2014
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Annals of hematology, 2014, Volume: 93, Issue:8 Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases	2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors	2014
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer immunology, immunotherapy : CII, 2014, Volume: 63, Issue:10 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dendritic Cells; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vincristine	2014
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bortezomib; Coagulants; Coagulation Protein Disorders; Dexamethasone; Doxorubicin; Female; Hematoma; Hematuria; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide	2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide	2014
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine	2014
Current treatment for multiple myeloma. The New England journal of medicine, 2014, Sep-04, Volume: 371, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide	2014
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report. Journal of medical case reports, 2014, Sep-08, Volume: 8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous	2014
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma. Hematological oncology, 2016, Volume: 34, Issue:1 Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult	2016
Precipitation of ventricular bigeminy by DMSO during autologous haematopoietic stem cell transplantation. Transfusion medicine (Oxford, England), 2015, Volume: 25, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Bortezomib; Cryoprotective Agents; Dexamethasone; Dimethyl Sulfoxide; Electrocardiography; Humans; Isotonic Solutions; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Ventricular Premature Complexes	2015
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:3 Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Mice; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Thalidomide; Tumor Microenvironment; Xenograft Model Antitumor Assays	2015
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. Acta haematologica, 2015, Volume: 133, Issue:4 Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey	2015
[Complications and managements in treatment of melphalan, prednisone and new agents]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide	2015
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Acta haematologica, 2015, Volume: 134, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide	2015
Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. Hematology/oncology and stem cell therapy, 2016, Volume: 9, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Lenalidomide; Lymph Nodes; Male; Mediastinal Neoplasms; Mediastinum; Melphalan; Middle Aged; Plasma Cells; Plasmacytoma; Syndecan-1; Thalidomide	2016
Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2015
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia, 2016, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome	2016
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. Journal of medical economics, 2016, Volume: 19, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States	2016
Lenalidomide - the new melphalan? Leukemia & lymphoma, 2016, Volume: 57, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Thalidomide	2016
Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy. Leukemia & lymphoma, 2016, Volume: 57, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Immunoglobulin G; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Paraproteinemias; Retrospective Studies; Scleromyxedema; Thalidomide; Treatment Outcome	2016
[Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide	2016
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood, 2016, 08-04, Volume: 128, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Transplantation, Autologous	2016
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine	2016
Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. Annals of hematology, 2016, Volume: 95, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Neoplasm Proteins; Peptide Hydrolases; Prednisolone; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases	2016
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. Asia-Pacific journal of clinical oncology, 2017, Volume: 13, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Thalidomide	2017
Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Cancer medicine, 2017, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisolone; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2017
An Adult with Polyneuropathy and Hypogonadism due to Poems Syndrome. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2017, Volume: 27, Issue:10 Topics: Adult; Dexamethasone; Female; Humans; Hypogonadism; Melphalan; Paraproteinemias; POEMS Syndrome; Polyneuropathies; Thalidomide; Treatment Outcome	2017
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood, 2018, 02-01, Volume: 131, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2018
[Extramedullary mediastinal plasmacytoma. Report of one case]. Revista medica de Chile, 2017, Volume: 145, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mediastinal Neoplasms; Mediastinoscopy; Melphalan; Plasmacytoma; Prednisone; Thalidomide; Tomography; Treatment Outcome	2017
[Treatment of systemic AL amyloidosis: about 25 cases]. The Pan African medical journal, 2017, Volume: 28 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Hospitals, Military; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome	2017
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation]. Bulletin du cancer, 2018, Volume: 105, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide	2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. Advances in therapy, 2018, Volume: 35, Issue:11 Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Female; Finland; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival; Thalidomide; Treatment Outcome	2018
Advances in POEMS treatment and the need to define standardised outcome measures. British journal of haematology, 2019, Volume: 185, Issue:2 Topics: Biomarkers; Humans; Lenalidomide; Melphalan; Outcome Assessment, Health Care; POEMS Syndrome; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A	2019
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal medicine journal, 2019, Volume: 49, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bortezomib; Female; Health Services Accessibility; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Immunosuppressive Agents; Induction Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; New Zealand; Progression-Free Survival; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome	2019
Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report. Medicine, 2018, Volume: 97, Issue:50 Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Psoriasis; Thalidomide; Transplantation, Autologous	2018
Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients. Clinical therapeutics, 2019, Volume: 41, Issue:6 Topics: China; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Immunosuppressive Agents; Kidney Diseases; Melphalan; Retrospective Studies; Thalidomide	2019
Editorial: Immunotherapy in Multiple Myeloma. Frontiers in immunology, 2019, Volume: 10 Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bortezomib; Humans; Immunotherapy; Melphalan; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family; Thalidomide	2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid Leukemia & lymphoma, 2020, Volume: 61, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2020
Hemophagocytic relapsed intramedullary plasmacytoma. International journal of hematology, 2020, Volume: 111, Issue:6 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2020
Pleural plasmacytomas - the role of radiotherapy. British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Pleural Neoplasms; Prednisolone; Thalidomide	2020
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European journal of haematology, 2021, Volume: 107, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Czech Republic; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Registries; Thalidomide; Treatment Outcome	2021